Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says

FDA says erythropoietin clinical effect cannot be generalized to different tumor types without data from biopsies. Amgen's Aranesp will undergo five survival studies; J&J will look at Procrit and Eprex in metastatic breast cancer patients with an endpoint of progression-free survival.